Entecavir (commercial name Baraclude) is an oral antiviral drug discovered at the pharmaceutical company Bristol-Myers Squibb; it is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.

This drug has been accepted by the US Food and Drug Administration (FDA) in March 2005; it is more efficient than an older Hepatitis B drug, lamivudine.

Official site

Antivirals